Display options
Cite
Cirioni O, Weimer LE, Fragola V, et al. A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation. West Indian Med J. 2013;63(7):779-84doi: 10.7727/wimj.2013.264.
Cirioni, O., Weimer, L. E., Fragola, V., Giacometti, A., Ancarani, F., Maracci, M., Gabrielli, E., Marchionni, E., Pirillo, M. F., & Vella, S. (2014). A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation. The West Indian medical journal, 63(7), 779-84. https://doi.org/10.7727/wimj.2013.264
Cirioni, O, et al. "A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation." The West Indian medical journal vol. 63,7 (2014): 779-84. doi: https://doi.org/10.7727/wimj.2013.264
Cirioni O, Weimer LE, Fragola V, Giacometti A, Ancarani F, Maracci M, Gabrielli E, Marchionni E, Pirillo MF, Vella S. A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation. West Indian Med J. 2014 Dec;63(7):779-84. doi: 10.7727/wimj.2013.264. Epub 2013 Sep 03. PMID: 25867565; PMCID: PMC4668968.
Copy Download .nbib Format: NLM
Share it on

West Indian Med J. 2014 Dec;63(7):779-84. doi: 10.7727/wimj.2013.264. Epub 2013 Sep 03.

A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.

The West Indian medical journal

O Cirioni, L E Weimer, V Fragola, A Giacometti, F Ancarani, M Maracci, E Gabrielli, E Marchionni, M F Pirillo, S Vella

Affiliations

  1. Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy.
  2. Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Viale Regina Elena, 299 00161, Rome, Italy. [email protected].
  3. Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy.

PMID: 25867565 PMCID: PMC4668968 DOI: 10.7727/wimj.2013.264

Abstract

In this case report, we examine the impact of a simplified two-drug highly active antiretroviral therapy (HAART) regimen of raltegravir and lamivudine in a patient co-infected with human immunodeficiency virus (HIV) and hepatitis C, D and B viruses (HCV/HDV/HBV) under immunosuppressive therapy after liver transplantation. Pharmacokinetic interactions between integrase inhibitors and immunosuppressant drugs are described. Raltegravir, the first integrase inhibitor, associated with lamivudine, was introduced because its metabolism does not interfere with immunosuppressant therapy. During post-orthotopic liver transplantation follow-up, the patient's transaminases level increased and his antiretroviral therapy (HAART) of tenofovir/emtricitabine and fosamprenavir was changed, due to suspected drug toxicity. After seven months of follow-up, the patient showed good tolerance, good viro-immunological control with undetectable HIV viraemia and stable concentrations of immunosuppressive drugs. This case indicates that the combination of raltegravir and lamivudine is an optimal and effective strategy because it resulted in an important reduction of hepatic transaminases in a patient with very critical clinical conditions.

References

  1. Am J Transplant. 2009 Aug;9(8):1946-52 - PubMed
  2. Kidney Int. 2004 Aug;66(2):532-41 - PubMed
  3. AIDS. 2008 Feb 19;22(4):547-8 - PubMed
  4. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33 - PubMed
  5. Lancet. 2007 Apr 14;369(9569):1261-9 - PubMed

Publication Types